Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.2215/CJN.08070715

http://scihub22266oqcxt.onion/10.2215/CJN.08070715
suck pdf from google scholar
C4934839!4934839!27073199
unlimited free pdf from europmc27073199    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi

pmid27073199      Clin+J+Am+Soc+Nephrol 2016 ; 11 (7): 1173-9
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Long?Term Renal Outcomes after Cisplatin Treatment #MMPMID27073199
  • Latcha S; Jaimes EA; Patil S; Glezerman IG; Mehta S; Flombaum CD
  • Clin J Am Soc Nephrol 2016[Jul]; 11 (7): 1173-9 PMID27073199show ga
  • Background and objectives: Nephrotoxicity remains the dose?limiting side effect of cisplatin, an effective chemotherapeutic agent with applications across diverse tumor types. This study presents data on renal outcomes across multiple tumor types in 821 adults. We report on incidence of AKI, initial and long-term changes in eGFR after cisplatin, and relationships between cumulative dose, initial eGFR, age, sex, and long?term renal function. Design, setting, participants, & measurements: This was a retrospective study of adult patients treated with cisplatin from January 1, 2000 to September 21, 2011 who had survived ?5 years after initial dose. The Modification of Diet in Renal Disease equation was used to calculate eGFR. AKI was defined as an increase from the baseline creatinine of >25% within 30 days after the first cycle of cisplatin. Chi-squared tests were done to evaluate the relationships between categorical or ordinal variables; ANOVAs or t tests were used to evaluate continuous or categorical variables. Changes in eGFR over time were evaluated in a growth curve model. Results: Mean follow-up was 6 years (25th and 75th percentiles, 4 and 9 years). AKI occurred in 31.5% of patients, with a median initial decline in eGFR of 10 ml/min per 1.73 m2 (25th and 75th percentiles, ?41.5 and ?23.3 ml/min per 1.73 m2). At any time point after the first cycle of cisplatin, <3% of patients progressed to eGFR<29 ml/min per 1.73 m2, and none were known to be on dialysis. Age was associated with a higher risk for AKI after cisplatin. Compared with age <25 years old, the odds ratios for AKI versus no AKI are 1.22 for >26?44 years old (95% confidence interval [95% CI], 0.60 to 2.4), 1.54 for >45?65 years old (95% CI, 0.78 to 3), and 2.96 for >66 years old (95% CI, 1.4 to 6.1). The lowest dose categories of cisplatin (?100 and 101?250 mg/m2) are associated with increases in eGFR (P=0.06 and P=0.02, respectively) compared with the highest dose category (>701 mg/m2). Conclusions: This is the largest study of adult patients with cancer who received cisplatin for treatment across multiple tumor types. Most patients experience small but permanent declines in eGFR, but none progressed to ESRD requiring hemodialysis.
  • ä


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box